- Home
- RDCM vs KPTI Comparison
RDCM vs KPTI Comparison
Compare RDCM & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDCM | KPTI |
|---|---|---|
| Founded | 1985 | 2008 |
| Country | Israel | United States |
| Employees | N/A | 228 |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 205.7M | 172.6M |
| IPO Year | 1999 | 2013 |
Fundamental Metrics
Financial Performance| Metric | RDCM | KPTI |
|---|---|---|
| Price | $11.60 | $9.61 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $18.00 | ★ $22.17 |
| AVG Volume (30 Days) | 94.4K | ★ 717.1K |
| Earning Date | 01-01-0001 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $146,067,000.00 |
| Revenue This Year | $11.50 | $0.84 |
| Revenue Next Year | $9.74 | $46.25 |
| P/E Ratio | $16.35 | ★ N/A |
| Revenue Growth | N/A | ★ 0.57 |
| 52 Week Low | $9.88 | $3.51 |
| 52 Week High | $15.14 | $10.99 |
Technical Indicators
Market Signals| Indicator | RDCM | KPTI |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 63.84 |
| Support Level | $10.77 | $5.69 |
| Resistance Level | $13.65 | N/A |
| Average True Range (ATR) | 0.70 | 1.06 |
| MACD | 0.00 | 0.09 |
| Stochastic Oscillator | 34.60 | 71.28 |
Price Performance
Historical ComparisonAbout RDCM Radcom Ltd.
Radcom Ltd Ltd is engaged in providing network intelligence, 5G ready cloud-native, network intelligence solutions for telecom operators transitioning to 5G. The company has a network intelligence solution for 5G namely Radcom ACE. Its products consist of Radcom Network Visibility, Radcom Service Assurance, and Radcom Network Insights. It has offices in Israel, the United States, Brazil, and India. Key revenue is derived from sales in North America.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).